KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Income from Continuing Operations (2016 - 2025)

Historic Income from Continuing Operations for Jazz Pharmaceuticals (JAZZ) over the last 17 years, with Q3 2025 value amounting to $251.5 million.

  • Jazz Pharmaceuticals' Income from Continuing Operations rose 1677.3% to $251.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$60.4 million, marking a year-over-year decrease of 11298.66%. This contributed to the annual value of $561.8 million for FY2024, which is 3444.83% up from last year.
  • Jazz Pharmaceuticals' Income from Continuing Operations amounted to $251.5 million in Q3 2025, which was up 1677.3% from -$718.4 million recorded in Q2 2025.
  • Jazz Pharmaceuticals' 5-year Income from Continuing Operations high stood at $251.5 million for Q3 2025, and its period low was -$718.4 million during Q2 2025.
  • Over the past 5 years, Jazz Pharmaceuticals' median Income from Continuing Operations value was $53.8 million (recorded in 2022), while the average stood at -$1.7 million.
  • As far as peak fluctuations go, Jazz Pharmaceuticals' Income from Continuing Operations plummeted by 64182.59% in 2022, and later surged by 111653.14% in 2023.
  • Jazz Pharmaceuticals' Income from Continuing Operations (Quarter) stood at -$32.3 million in 2021, then tumbled by 641.83% to -$240.0 million in 2022, then soared by 139.43% to $94.6 million in 2023, then surged by 102.01% to $191.1 million in 2024, then soared by 31.56% to $251.5 million in 2025.
  • Its Income from Continuing Operations was $251.5 million in Q3 2025, compared to -$718.4 million in Q2 2025 and $191.1 million in Q4 2024.